Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

PFIZER INC
Mes dernières consult.
Most popular
  Report  
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Pfizer Inc. : Study Shows Positive Results for Pfizer's Lyrica Treatment for Fibromyalgia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/19/2012 | 02:40pm CET
   By Saabira Chaudhuri 
 

Pfizer Inc. (>> Pfizer Inc.) said results of a late-stage study of its pregabalin controlled-release formulation as a treatment for fibromyalgia were positive.

The drug company said top-line results of a Phase 3 study evaluating pregabalin controlled-release formulation, also known as Lyrica, in patients with fibromyalgia indicated that it had a statistically significant positive effect compared with a placebo with regards to time to loss of therapeutic response.

Pfizer described fibromyalgia as a common pain condition in the U.S. affecting more than five million Americans and characterized by chronic widespread pain and tenderness lasting for three or more months.

The most recent study is the second of three Phase 3 studies of the pregabalin controlled-release formulation, which Pfizer said will determine the potential use of pregabalin as a once-a-day therapy.

Last week, Pfizer had revealed that a Phase 3 study showed Lyrica as a potential epilepsy treatment didn't meet the primary endpoint for a change in seizure frequency. Monday, the drug company noted that the final study in post-herpetic neuralgia is ongoing.

"Collectively, the results of these controlled-release studies will allow us to better understand the potential of a once-a-day pregabalin treatment regimen," said Steven J. Romano, head of Pfizer's Global Primary Care Business Unit's Medicines Development Group. "Reducing the number of times patients need to take their medicine per day while maintaining the same efficacy and safety profile could potentially provide a greater convenience and the potential to enhance treatment adherence and outcomes."

Shares edged up 12 cents to $23.98 in recent premarket trading. The stock has risen 22% in the past year.

Write to Saabira Chaudhuri at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Pfizer Inc.
Stocks mentioned in the article
ChangeLast1st jan.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER INC
02:09pPFIZER : Receives Positive CHMP Opinion for Two Hematology Medicines, MYLOTARG a..
AQ
02:08pPFIZER : Announces Update on European Marketing Authorization Application for SU..
AQ
02:08pPFIZER : Albert Bourla Elected to Pfizer's Board of Directors
AQ
11:21aPFIZER : Announces Update on European Marketing Authorization Application for SU..
AQ
02/23PFIZER INC : Change in Directors or Principal Officers, Financial Statements and..
AQ
02/23PFIZER : Findings in Carcinomas Reported from S.J. Edwards and Co-Researchers (A..
AQ
02/23PFIZER : Receives Breakthrough Therapy Designation from FDA for PF-04965842, an ..
AQ
02/23PFIZER : Investigators from Pfizer Have Reported New Data on Brain Research (Pre..
AQ
02/23PFIZER : Researchers from Pfizer Describe Findings in Enzymes and Coenzymes (Ide..
AQ
02/23PFIZER : U.S., EU and Japan Health Authorities Accept Regulatory Submissions for..
AQ
More news
News from SeekingAlpha
2015Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update 
2015Antibiotics Stocks To Benefit From 21st Century Cures Act 
2015ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case 
2015DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb 
2015Pfizer's GL-2045 an Orphan Drug for CIDP 
Financials ($)
Sales 2018 54 410 M
EBIT 2018 20 806 M
Net income 2018 13 101 M
Debt 2018 22 213 M
Yield 2018 3,85%
P/E ratio 2018 16,31
P/E ratio 2019 15,17
EV / Sales 2018 4,33x
EV / Sales 2019 4,19x
Capitalization 213 B
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 40,3 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC213 155
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%222 939
PFIZER-1.33%213 155
ROCHE HOLDING LTD.-9.41%207 036
MERCK AND COMPANY-3.02%148 618